Sofinicline: A novel nicotinic acetylcholine receptor agonist in the treatment of attention-deficit/hyperactivity disorder

Expert Opinion on Investigational Drugs

Volumn 23, Issue 8, 2014, Pages 1157-1163

  Fleisher, Carl ^a   Mcgough, James ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Attention deficit hyperactivity disorder; Nicotinic agonist; Non stimulant; Sofinicline

Indexed keywords

3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; ALPRENOLOL; ATOMOXETINE; BRADANICLINE; EB 1020; ISPRONICLINE; MG 01C 1; NICOTINIC RECEPTOR; ORADUR; PALLADIUM; PD 2005; PD 9475; POZANICLINE; SOFINICLINE; UNCLASSIFIED DRUG; 3-(5,6-DICHLOROPYRIDIN-3-YL)-3,6-DIAZABICYCLO(3.2.0)HEPTANE; AZABICYCLO DERIVATIVE; NICOTINIC AGENT; NICOTINIC RECEPTOR ALPHA4BETA2; PROPYLAMINE; PYRIDINE DERIVATIVE;

ATTENTION DEFICIT DISORDER; COGNITION; DRUG EFFICACY; DRUG LEGISLATION; DRUG MARKETING; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; ETIOLOGY; HUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; ANIMAL; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; COMPARATIVE STUDY; DRUG EFFECTS; METABOLISM; PATHOPHYSIOLOGY;

ANIMALS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; AZABICYCLO COMPOUNDS; HUMANS; NICOTINIC AGONISTS; PROPYLAMINES; PYRIDINES; RECEPTORS, NICOTINIC;

EID: 84904307327     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2014.934806     Document Type: Review

References (67)

1. Wolraich ML, McKeown RE, Visser SN, et al. The prevalence of ADHD: Its diagnosis and treatment in four school districts across two states. J Atten Disord 2012. [Epub ahead of print]
2. Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: Results from the National Comorbidity Survey Replication. Am J Psychiatry 2006;163: 716-23
3. Fayyad J, De Graaf R, Kessler R, et al. Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry 2007;190: 402-9
4. Pliszka S; AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007;46: 894-921
5. Faraone SV. Using meta-Analysis to compare the efficacy of medications for attention-deficit/hyperactivity disorder in youths. P T 2009;34: 678-94
6. Molina BSG, Hinshaw SP, Swanson JM, et al. The MTA at 8 years: Prospective follow-up of children treated for combined-Type ADHD in a multisite study. J Am Acad Child Adolesc Psychiatry 2009;48: 484-500
7. Spencer TJ, Wilens TE, Biederman J, et al. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: A 4-week, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2006;28: 266-79
8. Toomey SL, Sox CM, Rusinak D, Finkelstein JA. Why do children with ADHD discontinue their medicatioñ Clin Pediatr (Phila) 2012;51: 763-9
9. Kollins SH. A qualitative review of issues arising in the use of psycho-stimulant medications in patients with ADHD and co-morbid substance use disorders. Curr Med Res Opin 2008;24: 1345-57
10. Charach A, Fernandez R. Enhancing ADHD medication adherence: Challenges and opportunities. Curr Psychiatry Rep 2013;15(7): 371
11. Pliszka SR, Crismon ML, Hughes CW, et al. The Texas Children's Medication Algorithm Project: Revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2006;45: 642-57
12. Faraone SV, Glatt SJ. A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-Analysis of effect sizes. J Clin Psychiatry 2010;71: 754-63
13. Sallee F, Connor DF, Newcorn JH. A review of the rationale and clinical utilization of alpha2-Adrenoceptor agonists for the treatment of attentiondeficit/ hyperactivity and related disorders. J Child Adolesc Psychopharmacol 2013;23: 308-19
14. Moriyama TS, Polanczyk GV, Terzi FS, et al. Psychopharmacology and psychotherapy for the treatment of adults with ADHD-A systematic review of available meta-Analyses. CNS Spectr 2013;18: 296-306
15. Stahl SM, Mignon L. Attention deficit hyperactivity disorder. Cambridge University Press, Cambridge, New York; 2010
16. Levin ED, McClernon FJ, Rezvani AH. Nicotinic effects on cognitive function: Behavioral characterization, pharmacological specification, and anatomic localization. Psychopharmacology (Berl)2006;184: 523-39
17. Levin ED, Cauley M, Rezvani AH. Improvement of attentional function with antagonism of nicotinic receptors in female rats. Eur J Pharmacol 2013;702: 269-74
18. Potter AS, Ryan KK, Newhouse PA. Effects of acute ultra-low dose mecamylamine on cognition in adult attention-deficit/hyperactivity disorder (ADHD). Hum Psychopharmacol 2009;24: 309-17
19. Levin ED, Caldwell DP. Low-dose mecamylamine improves learning of rats in the radial-Arm maze repeated acquisition procedure. Neurobiol Learn Mem 2006;86: 117-22
20. Buccafusco JJ, Jackson WJ, Terry AV Jr, et al. Improvement in performance of a delayed matching-To-sample task by monkeys following ABT-418: A novel cholinergic channel activator for memory enhancement. Psychopharmacology (Berl) 1995;120: 256-66
21. Vidal C. Nicotinic receptors in the brain. Molecular biology, function, and therapeutics. Mol Chem Neuropathol 1996;28: 3-11
22. Dunbar GC, Kuchibhatla R. Cognitive enhancement in man with ispronicline, a nicotinic partial agonist. J Mol Neurosci 2006;30: 169-72
23. Hosford D, Dunbar G, Lieberman JA, Segreti A. The alpha7 neuronal nicotinic receptor (NNR) modulator TC-5619 had beneficial effects and was generally well tolerated in a Phase 2 trial in cognitive dysfunction in schizophrenia (CDS). American College of Neuropsychopharmacology; 2011. Waikoloa, Hawaii
24. Prendergast MA, Jackson WJ, Terry AV Jr, et al. Central nicotinic receptor agonists ABT-418, ABT-089, and (-)-nicotine reduce distractibility in adult monkeys. Psychopharmacology (Berl) 1998;136: 50-8
25. Apostol G, Abi-Saab W, Kratochvil CJ, et al. Efficacy and safety of the novel alpha4beta2 neuronal nicotinic receptor partial agonist ABT-089 in adults with attention-deficit/hyperactivity disorder: A randomized, double-blind, placebo-controlled crossover study. Psychopharmacology (Berl) 2011;219: 715-25
26. Bain EE, Apostol G, Sangal RB, et al. A randomized pilot study of the efficacy and safety of ABT-089, a novel alpha4beta2 neuronal NICOTINIC receptor agonist, in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2012;73: 783-9
27. Wilens TE, Verlinden MH, Adler LA, et al. ABT-089, a neuronal nicotinic receptor partial agonist, for the treatment of attention-deficit/hyperactivity disorder in adults: Results of a pilot study. Biol Psychiatry 2006;59: 1065-70
28. Wilens TE, Gault LM, Childress A, et al. Safety and efficacy of ABT-089 in pediatric attention-deficit/hyperactivity disorder: Results from two randomized placebo-controlled clinical trials. J Am Acad Child Adolesc Psychiatry 2011;50: 73-84.e1
29. Potter AS, Dunbar G, Mazzulla E, et al. AZD3480, a novel nicotinic receptor agonist, for the treatment of attention-deficit/hyperactivity disorder in adults. Biol Psychiatry 2014;75: 207-14
30. Scheffler RM, Hinshaw SP, Modrek S, Levine P. The global market for ADHD medications. Health Aff (Millwood)2007;26: 450-7
31. ORADUR-ADHD Program. Products. Durect Corp., Cupertino, CA; 2013. Available from: Http: //www.durect. com/wt/durect/page-name/oradur-Adhd [Last accessed 12 January 2014]
32. Nicotinics Monthly. UpdatesPlus. LeadDiscovery, Bodiam, UK; 2012. Available from: Http: //www. leaddiscovery.co.uk/admin/upload/files/% 20UpdatesPlus-Nicotinics-Sept-Oct12% 20example.pdf [Last accessed 18 January 2014]
33. NeuroSearch: ABT-894 remains viable option for ADHD following neuropathic pain failure. News. Datamonitor Research Store, New York, NY; 2009. Available from: Http: //www. datamonitor.com/store/News/ neurosearch-Abt-894-remains- viable-option-for-Adhd-following-neuropathic-pain-failure?productid= 2D5D97F8-CBDA-4B2D-A291-253ADB570F10 [Last accessed 12 February 2014]
34. Ji J, Schrimpf MR, Sippy KB, et al. Synthesis and structure-Activity relationship studies of 3, 6-diazabicyclo [3.2.0]heptanes as novel alpha4beta2 nicotinic acetylcholine receptor selective agonists. J Med Chem 2007;50: 5493-508
35. Sofinicline, CID= 10131048. Compound Summary. National Institutes of Health, National Center for Biotechnology Information, PubChem Compound Database. Washington, DC; 2014. Available from: Http: //pubchem. ncbi.nlm.nih.gov/summary/summary.cgi? cid=10131048 [Last accessed 12 January 2014]
36. Wilens TE, Decker MW. Nueronal nicotinic receptor agonists for the treatment of attention-deficit/ hyperactivity disorder: Focus on cognition. Biochem Pharmacol 2007;74: 1212-23
37. Bain EE, Abi-Saab WM, Dutta S, et al. Sofinicline (abt-894) for attention-deficit/ hyperactivity disorder. WO2009149003 A1; 2009
38. Bain EE, Robieson W, Pritchett Y, et al. A randomized, double-blind, placebocontrolled phase 2 study of alpha4beta2 agonist ABT-894 in adults with ADHD. Neuropsychopharmacology 2013;38: 405-13
39. ABT-894. Other assets. Neurosearch, Copenhagen, Denmark; 2014. Available from: Http: //neurosearch.com/ Default.aspxi?D=8266 [Last accessed 26 March 2014]
40. Home. ClinicalTrials.gov. National Institutes of Health, Washington, DC; 2014. Available from: Http: //clinicaltrials. gov/ [Last accessed 26 March 2014]
41. Home and Search. EU Clinical Trials Register. European Medicines Agency, London, England, UK; 2014. Available from: Https: //www. clinicaltrialsregister. eu/ctr-search/search; jsessionid=RJjvTJZQfzRH0T8vwWy GcHflpTqWfSDjh03mTQYhyvX5dxRt DWWh!164305626 [Last accessed 26 March 2014]
42. McClernon FJ, Fuemmeler B, Kollins S, et al. Interactions between genotype and retrospective ADHD symptoms predict lifetime smoking risk in a sasmple of young adults. Nicotine Tob Res 2008;10: 117-27
43. Levin ED, Conners CK, Sparrow E, et al. Nicotine effects on adults with attention-deficit/hyperactivity disorder. Psychopharmacology (Berl) 1996;123: 55-63
44. Montoya A, Hervas A, Cardo E, et al. Evaluation of atomoxetine for first-line treatment of newly diagnosed, treatmentnaïve children and adolescents with attention deficit/hyperactivity disorder. Curr Med Res Opin 2009;25: 2745-54
45. Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: A randomized, placebo-controlled study. Am J Psychiatry 2002;159: 1896-901
46. Gau SSF, Huang Y-S, Soong W-T, et al. A randomized, double-blind, placebo-controlled clinical trial on oncedaily atomoxetine in Taiwanese children and adolescents with attention-deficit/ hyperactivity disorder. J Child Adolesc Psychopharmacol 2007;17: 447-60
47. Svanborg P, Thernlund G, Gustafsson PA, et al. Efficacy and safety of atomoxetine as add-on to psychoeducation in the treatment of attention deficit/hyperactivity disorder: A randomized, double-blind, placebocontrolled study in stimulant-naïve Swedish children and adolescents. Eur Child Adolesc Psychiatry 2009;18: 240-9
48. Michelson D, Adler L, Spencer T, et al. Atomoxetine in adults with ADHD: Two randomized, placebo-controlled studies. Biol Psychiatry 2003;53: 112-20
49. Sutherland SM, Adler LA, Chen C, et al. An 8-week, randomized controlled trial of atomoxetine, atomoxetine plus buspirone, or placebo in adults with ADHD. J Clin Psychiatry 2012;73: 445-50
50. Young JL, Sarkis E, Qiao M, Wietecha L. Once-daily treatment with atomoxetine in adults with attentiondeficit/ hyperactivity disorder: A 24-week, randomized, double-blind, placebo-controlled trial. Clin Neuropharmacol 2011;34: 51-60
51. Jain R, Segal S, Kollins SH, Khayrallah M. Clonidine extendedrelease tablets for pediatric patients with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2011;50: 171-9
52. Biederman J, Melmed RD, Patel A, et al. A randomized, double-blind, placebocontrolled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics 2008;121: E73-84
53. Sallee FR, Lyne A, Wigal T, McGough JJ. Long-Term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2009;19: 215-26
54. Hurst R, Rollema H, Bertrand D. Nicotinic acetylcholine receptors: From basic science to therapeutics. Pharmacol Ther 2013;137: 22-54
55. Todd RD, Neuman RJ. Gene-environment interactions in the development of combined type ADHD: Evidence for a synapse-based model. Am J Med Genet Part B Neuropsychiatr Genet 2007;144B: 971-5
56. Guan L, Wang B, Chen Y, et al. A highdensity single-nucleotide polymorphism screen of 23 candidate genes in attention deficit hyperactivity disorder: Suggesting multiple susceptibility genes among Chinese Han population. Mol Psychiatry 2009;14: 546-54
57. Stergiakouli E, Hamshere M, Holmans P, deCODE Genetics. et al. Investigating the contribution of common genetic variants to the risk and pathogenesis of ADHD. Am J Psychiatry 2012;169: 186-94
58. Williams NM, Franke B, Mick E, et al. Genome-wide analysis of copy number variants in attention deficit hyperactivity disorder: The role of rare variants and duplications at 15q13.3. Am J Psychiatry 2012;169: 195-204
59. Lee J, Laurin N, Crosbie J, et al. Association study of the nicotinic acetylcholine receptor alpha4 subunit gene, CHRNA4, in attention-deficit hyperactivity disorder. Genes Brain Behav 2008;7: 53-60
60. Manor I, Ben-Hayun R, Aharon-Peretz J, et al. A randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy, safety, and tolerability of extended-release metadoxine in adults with attentiondeficit/ hyperactivity disorder. J Clin Psychiatry 2012;73: 1517-23
61. Alcobra's ADHD Program Moving To Pediatrics. Alerts. Seeking Alpha, Pittsburgh, PA; 2014. Available from: Http: //seekingalpha.com/article/1946961- Alcobras-Adhd-program-moving-Topediatrics [Last accessed 12 February 2014]
62. DURECT Announces Selection with Orient PHARMA of Lead Formulation for ORADUR-Methylphenidate. Press Release. PR Newswire, New York, NY; 2013. Available from: Http: //www. prnewswire.com/news-releases/durectannounces- selection-with-orient-pharmaof-lead-formulation-for-oradurmethylphenidate- 217906421.html [Last accessed 12 January 2014]
63. Neurovance Raises $7 Million for ADHD Drug Development. Articles. Xconomy, Inc., Cambridge, MA; 2012. Available from: Http: //www. xconomy.com/boston/%202012/10/19/% 20neurovance-raises-7-million-for-Adhddrug- development/ [Last accessed 12 January 2014]
64. Cincinnati company developing new ADHD drug. Innovation + Startup News. Soapbox Media, Cincinnati, OH; 2012. Available from: Http: //www. soapboxmedia.com/innovationnews/ 073112p2d.aspx [Last accessed 12 January 2014]
65. Product Pipeline: PD2005 for Attention Deficit Hyperactivity Disorder. Products. P2D Bioscience, Cincinnati, OH; 2012. Available from: Http: //www. p2dinc.com/products.html [Last accessed 12 January 2014]
66. Targacept to discontinue development of TC-5619 for ADHD, eliminate jobs. Top Story. FirstWordPharma, London, UK; 2012. Available from: Http: //www.firstwordpharma.com/node/ 1017523 [Last accessed 11 June 2014]
67. Safety and Efficacy of GTS21 in Adults With Attention-deficit Hyperactivity Disorder. Clinical Trial. TrialBulletin. com, Haverhill, UK; 2014. Available from: Http: //trialbulletin.com/ lib/entry/ct-00419445 [Last accessed 11 June 2014].